Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin) - Mismetti, P; Laporte-Simitsidis, S; Navarro, C (Thromb Haemost, 1998)